Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR

CONCLUSIONS: Preliminary results from the FIH study with DurAVR THV demonstrate a good safety profile with promising haemodynamic performance sustained at 1 year and restoration of near-normal flow dynamics. Further clinical investigation is warranted to evaluate how DurAVR THV may play a role in addressing the challenge of lifetime management in AS patients.PMID:37334801 | DOI:10.4244/EIJ-D-23-00282

Source: EuroIntervention - June 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Susheel K Kodali Paul Sorajja Christopher U Meduri Kari Feldt Jo ão L Cavalcante Pankaj Garg Nadira Hamid Karl K Poon Magnus R M Settergren Marcus R Burns Andreas R ück Janarthanan Sathananthan Alan Zajarias Tamaz Shaburishvili Teona Zirakashvili Maia Z Source Type: research